Literature DB >> 16140923

Somatic mutations of the protein kinase gene family in human lung cancer.

Helen Davies1, Chris Hunter, Raffaella Smith, Philip Stephens, Chris Greenman, Graham Bignell, Jon Teague, Adam Butler, Sarah Edkins, Claire Stevens, Adrian Parker, Sarah O'Meara, Tim Avis, Syd Barthorpe, Lisa Brackenbury, Gemma Buck, Jody Clements, Jennifer Cole, Ed Dicks, Ken Edwards, Simon Forbes, Matthew Gorton, Kristian Gray, Kelly Halliday, Rachel Harrison, Katy Hills, Jonathon Hinton, David Jones, Vivienne Kosmidou, Ross Laman, Richard Lugg, Andrew Menzies, Janet Perry, Robert Petty, Keiran Raine, Rebecca Shepherd, Alexandra Small, Helen Solomon, Yvonne Stephens, Calli Tofts, Jennifer Varian, Anthony Webb, Sofie West, Sara Widaa, Andrew Yates, Francis Brasseur, Colin S Cooper, Adrienne M Flanagan, Anthony Green, Maggie Knowles, Suet Y Leung, Leendert H J Looijenga, Bruce Malkowicz, Marco A Pierotti, Bin T Teh, Siu T Yuen, Sunil R Lakhani, Douglas F Easton, Barbara L Weber, Peter Goldstraw, Andrew G Nicholson, Richard Wooster, Michael R Stratton, P Andrew Futreal.   

Abstract

Protein kinases are frequently mutated in human cancer and inhibitors of mutant protein kinases have proven to be effective anticancer drugs. We screened the coding sequences of 518 protein kinases (approximately 1.3 Mb of DNA per sample) for somatic mutations in 26 primary lung neoplasms and seven lung cancer cell lines. One hundred eighty-eight somatic mutations were detected in 141 genes. Of these, 35 were synonymous (silent) changes. This result indicates that most of the 188 mutations were "passenger" mutations that are not causally implicated in oncogenesis. However, an excess of approximately 40 nonsynonymous substitutions compared with that expected by chance (P = 0.07) suggests that some nonsynonymous mutations have been selected and are contributing to oncogenesis. There was considerable variation between individual lung cancers in the number of mutations observed and no mutations were found in lung carcinoids. The mutational spectra of most lung cancers were characterized by a high proportion of C:G > A:T transversions, compatible with the mutagenic effects of tobacco carcinogens. However, one neuroendocrine cancer cell line had a distinctive mutational spectrum reminiscent of UV-induced DNA damage. The results suggest that several mutated protein kinases may be contributing to lung cancer development, but that mutations in each one are infrequent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140923     DOI: 10.1158/0008-5472.CAN-05-1855

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  183 in total

Review 1.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

2.  Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation.

Authors:  Larissa S Moniz; Vuk Stambolic
Journal:  Mol Cell Biol       Date:  2010-10-18       Impact factor: 4.272

Review 3.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

4.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

Authors:  William Lee; Zhaoshi Jiang; Jinfeng Liu; Peter M Haverty; Yinghui Guan; Jeremy Stinson; Peng Yue; Yan Zhang; Krishna P Pant; Deepali Bhatt; Connie Ha; Stephanie Johnson; Michael I Kennemer; Sankar Mohan; Igor Nazarenko; Colin Watanabe; Andrew B Sparks; David S Shames; Robert Gentleman; Frederic J de Sauvage; Howard Stern; Ajay Pandita; Dennis G Ballinger; Radoje Drmanac; Zora Modrusan; Somasekar Seshagiri; Zemin Zhang
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

5.  Eph receptor and mTOR pathway crosstalk: implications for cancer.

Authors:  Mustafa Sahin
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

6.  Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.

Authors:  Michihiro Mori; Toshinori Mori; Aina Yamamoto; Shoji Takagi; Masatsugu Ueda
Journal:  Hum Cell       Date:  2019-04-08       Impact factor: 4.174

7.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.

Authors:  Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  Mutations in critical domains confer the human mTOR gene strong tumorigenicity.

Authors:  Avaniyapuram Kannan Murugan; Ali Alzahrani; Mingzhao Xing
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

Review 9.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 10.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.